Literature DB >> 24747357

Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.

Eunju Shin1, James T Rogers2, Paola Devoto3, Anders Björklund2, Manolo Carta3.   

Abstract

Parkinson's disease (PD) is characterized by progressive loss of dopaminergic (DA) neurons in the substantia nigra. However, studies of post-mortem PD brains have shown that not only DA neurons but also the noradrenergic (NA) neurons in the locus coeruleus degenerate, and that the NA neurodegeneration may be as profound, and also precede degeneration of the midbrain DA neurons. Previous studies in animal models of PD have suggested that loss of forebrain NA will add to the development of motor symptoms in animals with lesions of the nigrostriatal DA neurons, but the results obtained in rodents have been inconclusive due to the shortcomings of the toxin, DSP-4, used to lesion the NA projections. Here, we have developed an alternative double-lesion paradigm using injections of 6-OHDA into striatum in combination with intraventricular injections of a powerful NA immunotoxin, anti-DBH-Saporin, to eliminate the NA neurons in the locus coeruleus, and associated pontine nuclei. Animals with combined DA and NA lesions were more prone to develop L-DOPA-induced dyskinesia, even at low L-DOPA doses, and they performed significantly worse in tests of reflexive and skilled paw use, the stepping and staircase tests, compared to DA-only lesioned rats. Post-mortem analysis revealed that NA depletion did not affect the degree of DA depletion, or the loss of tyrosine hydroxylase-positive innervation in the striatum. Cell loss in the substantia nigra was similar in both single and double lesioned animals, showing that the worsening effect was not due to increased loss of nigral DA neurons. The results show that damage to brainstem NA neurons, contributes to the development of motor impairments and the appearance of L-DOPA-induced dyskinesia in 6-OHDA lesioned rats, and provide support for the view that the development of motor symptoms and dyskinetic side effects in PD patients reflects the combined loss of midbrain DA neurons and NA neurons.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DBH-Saporin; L-DOPA-induced dyskinesia; Locus coeruleus; Motor impairment; Noradrenaline; Parkinson's disease; Staircase test

Mesh:

Substances:

Year:  2014        PMID: 24747357     DOI: 10.1016/j.expneurol.2014.04.011

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  18 in total

1.  Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.

Authors:  Ariana Q Farrand; Kristi L Helke; Rebecca A Gregory; Monika Gooz; Vanessa K Hinson; Heather A Boger
Journal:  Brain Stimul       Date:  2017-08-24       Impact factor: 8.955

Review 2.  Molecular imaging of levodopa-induced dyskinesias.

Authors:  Flavia Niccolini; Lorenzo Rocchi; Marios Politis
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

3.  Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Christopher J Barnum; Jessica A George; Margaret A Surrena; Christopher Bishop
Journal:  J Neurochem       Date:  2015-04-27       Impact factor: 5.372

4.  Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.

Authors:  Kinga Kamińska; Tomasz Lenda; Jolanta Konieczny; Elżbieta Lorenc-Koci
Journal:  Psychopharmacology (Berl)       Date:  2022-09-30       Impact factor: 4.415

Review 5.  Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease.

Authors:  David Weinshenker
Journal:  Trends Neurosci       Date:  2018-02-20       Impact factor: 13.837

6.  Downregulation of the Central Noradrenergic System by Toxoplasma gondii Infection.

Authors:  Isra Alsaady; Ellen Tedford; Mohammad Alsaad; Greg Bristow; Shivali Kohli; Matthew Murray; Matthew Reeves; M S Vijayabaskar; Steven J Clapcote; Jonathan Wastling; Glenn A McConkey
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

7.  Apathy and Anxiety in De Novo Parkinson's Disease Predict the Severity of Motor Complications.

Authors:  Jared T Hinkle; Kate Perepezko; Lorenzo L Gonzalez; Kelly A Mills; Gregory M Pontone
Journal:  Mov Disord Clin Pract       Date:  2020-12-04

Review 8.  Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications.

Authors:  M Angela Cenci
Journal:  Front Neurol       Date:  2014-12-15       Impact factor: 4.003

9.  Restoration of MPTP-induced deficits by exercise and Milmed(®) co-treatment.

Authors:  Trevor Archer; Danilo Garcia; Anders Fredriksson
Journal:  PeerJ       Date:  2014-08-26       Impact factor: 2.984

10.  α-Synuclein induced toxicity in brain stem serotonin neurons mediated by an AAV vector driven by the tryptophan hydroxylase promoter.

Authors:  Oi Wan Wan; Eunju Shin; Bengt Mattsson; Dorian Caudal; Per Svenningsson; Anders Björklund
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.